Asia Spotlight: Wockhardt’s GMP Issues Lead FDA To Urge Global Review Of Manufacturing Operations
Executive Summary
FDA finds company lacks a robust quality management system at its India sites and manipulated crucial manufacturing data. Warning letter is latest in series of FDA actions on the firm, suggests concerns with integrity of all firm’s data.